(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Rebecca Gayheart on her 'very complicated' relationship with Eric Dane: 'I am always going to want the best for him' - 2Is Chinese food truly flavorful?
- 3Who is Adm. Frank 'Mitch' Bradley and what does he have to do with the Venezuela boat strikes?
- 4Extraordinary Guinness World Records That Will Astound You
- 5The architect of Iran’s military survival remains defiant
- Israeli lawmakers pass bill reviving death penalty for terrorists
- Nexi expands alliance with PayPal
- Latvia seeks emergency UN meeting over Russian missile attack on Lviv
- Gilead's new HIV prevention shot added to CVS's drug coverage lists, CEO says
- 6 Methods for further developing Rest Quality
- Israeli naval intelligence reduces Iranian threat to Strait of Hormuz
- NASA Artemis II tracker: Crew less than 60,000 miles from moon ahead of Monday flyby
- What is colostrum? And should you be taking it?
- 'Tangled' live-action movie casts Teagan Croft and Milo Manheim as Rapunzel and Flynn
